BioSpace News Archive

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced that the Centers for Medicare and Medicaid Services (CMS) has issued a permanent product-specific J-code for DEXTENZA®

Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that Derrick Li, Head of Strategy for the Company, will present at Cantor Fitzgerald’s 2019 Global Healthcare Conference

Dicerna™ Pharmaceuticals, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved the grant of inducement stock options to purchase a total of 229,000 shares of common stock to be distributed among 10 new employees, with a grant date of October 1, 2019.

Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS – Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic gene-edited CAR T-cells (UCART), and Lonza (SWX: LONN), announced today that the companies have entered into a manufacturing service agreement covering clinical manufacturing of Cellectis’ allogeneic UCART product candidates targeting hematological malignancies.

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that multiple maralixibat abstracts will be presented at The Liver Meeting® 2019

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company bringing to market its proprietary CellFX™ System harnessing Nano-Pulse Stimulation™ (NPS™) technology, today announced podium presentations of its NPS technology at two premier medical aesthetics meetings

Author John Hawkins has written a well-researched biography about Termeer’s legacy—how he built a global biotech giant, Genzyme, and mentored a new generation of business leaders who continue to relentlessly challenge conventional innovation models and bring new novel treatments to patients around the world.

The Eye Institute of Alberta held their second annual Eye Ball Gala on Saturday, September 28 at the Westin Hotel, generating awareness and support for research into ocular degenerative disorders.

The U.S. Department’s Economic Development Administration (EDA) announced on Sept. 30, that it is investing $28.6 million in the University of the Virgin Islands to support efforts to diversify and strengthen the resiliency of the economy by helping to grow the medical sector, primarily by investing in the medical school project and the medical simulation center.

Researchers from Intermountain Healthcare and Stanford University say 10 seconds is about how quickly a new system they studied that utilizes artificial intelligence took to accurately identify key findings in chest X-rays of patients in the emergency department suspected of having pneumonia.